Elsevier

Annals of Oncology

Volume 28, Issue 7, July 2017, Pages 1448-1456
Annals of Oncology

Reviews
Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma

https://doi.org/10.1093/annonc/mdx169Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

Intratumoral heterogeneity (ITH) has increasingly being described for multiple cancers as the root cause of therapy resistance. Recent studies have started to explore the scope of ITH in glioblastoma (GBM), a highly aggressive and fatal form of brain tumor, to explain its inevitable therapy resistance and disease relapse. In this review, we detail the emerging data that explores the extensive genetic, cellular and functional ITH present in GBM. We discuss current experimental models of human GBM recurrence and suggest harnessing new technologies (CRISPR-Cas9 screening, CyTOF, cellular barcoding, single cell analysis) to delineate GBM ITH and identify treatment-refractory cell populations, thus opening new therapeutic windows. We will also explore why current therapeutics have failed in clinical trials and how ITH can inform us on developing empiric therapies for the treatment of recurrent GBM.

Key words

glioblastoma
intratumoral heterogeneity
brain tumor initiating cells
recurrence
models of resistance
polytherapy

Cited by (0)